Aadi Bioscience Yönetim

Yönetim kriter kontrolleri 2/4

Aadi Bioscience CEO'su Dave Lennon, Oct2023 tarihinde atandı, in görev süresi 1.08 yıldır. in toplam yıllık tazminatı $ 2.14M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.5% maaş ve 92.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.093% ine doğrudan sahiptir ve bu hisseler € 50.51K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.4 yıl ve 3.3 yıldır.

Anahtar bilgiler

Dave Lennon

İcra Kurulu Başkanı

US$2.1m

Toplam tazminat

CEO maaş yüzdesi	7.5%
CEO görev süresi	1.1yrs
CEO sahipliği	0.09%
Yönetim ortalama görev süresi	2.4yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Dave Lennon'un ücretlendirmesi Aadi Bioscience'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$62m
Jun 30 2024	n/a	n/a	-US$65m
Mar 31 2024	n/a	n/a	-US$69m
Dec 31 2023	US$2m	US$160k	-US$66m

Tazminat ve Piyasa: Dave 'nin toplam tazminatı ($USD 2.14M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 471.55K ).

Tazminat ve Kazançlar: Dave şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Dave Lennon (53 yo)

1.1yrs

Görev süresi

US$2,135,687

Tazminat

Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Lennon	President	1.1yrs	US$2.14m	0.093% € 50.5k
Scott Giacobello	CFO, Treasurer	3yrs	US$1.97m	0% € 0
Stephen Rodin	Senior VP of Legal & General Counsel	2.8yrs	Veri yok	Veri yok
Raymond Steitz	Senior VP of Human Resources & Chief Human Resources Officer	2.4yrs	Veri yok	Veri yok
Bryan Ball	Chief Technical Operations Officer	2.3yrs	Veri yok	0.41% € 220.9k

2.4yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: 3350 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Lennon	President	1.1yrs	US$2.14m	0.093% € 50.5k
Caley Castelein	Independent Chairman of the Board	3.3yrs	US$258.91k	0.080% € 43.5k
Emma Reeve	Independent Director	3.2yrs	US$240.91k	0% € 0
Anupam Dalal	Independent Director	3.3yrs	US$235.91k	0.0046% € 2.5k
Karin Hehenberger	Independent Director	3.3yrs	US$227.41k	0% € 0
Richard Maroun	Independent Director	7.8yrs	US$240.91k	0% € 0
Mohammad Hirmand	Independent Director	1.7yrs	US$345.60k	0% € 0
Behzad Aghazadeh	Independent Director	3.3yrs	US$225.41k	0% € 0

3.3yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 3350 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Aadi Bioscience Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Aadi Bioscience, Inc. Announces Executive Changes

High number of new directors

High number of new directors

High number of new directors

Aadi Bioscience, Inc. Announces Management Changes

Recent updates

Aadi Bioscience, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce

Aadi Bioscience Provides PRECISION1 Trial Updates

Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.67 loss in 2Q 2023)

Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

New minor risk - Profitability

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022)

Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.68 loss in 3Q 2022)

New minor risk - Market cap size

Aadi Bioscience, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$0.87 loss in 2Q 2022)

Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022)

High number of new directors

High number of new directors

High number of new directors

Aadi Bioscience, Inc. Announces Management Changes

High number of new directors

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$9.17 loss in 3Q 2021)

Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023

Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium

Now 21% undervalued

Second quarter 2022 earnings released: US$0.87 loss per share (vs US$0.22 loss in 2Q 2021)

Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Present at 2022 ASCO Annual Meeting

High number of new directors

First quarter 2022 earnings released: US$0.66 loss per share (vs US$0.71 loss in 1Q 2021)

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services

High number of new directors

Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

Aadi Bioscience, Inc. Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa

Interim Chief Financial Officer Lance Thibault has left the company

Aadi Bioscience, Inc. Announces FDA Approval of Its First Product Fyarro™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

No independent directors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş